Beauty

Novo Nordisk Looks Beyond Weight Loss to Longevity and Aesthetics

Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.

Related posts

Estée Lauder Companies and Puig End M&A Talks

Raven Ward

Luxury Superweek: Q1 Sales and Kering’s Strategy Reveal

Raven Ward

Is Armani Any Closer to a Stake Sale?

Raven Ward